论文部分内容阅读
目的:探讨分析不同化疗方案联合手术治疗非小细胞肺癌的临床疗效以及对患者免疫功能的影响。方法:经病理学证实的非小细胞肺癌患者94例,随机数字表法将其分为顺铂组与洛铂组,各47例。2组患者均采取手术治疗,并术前行辅助化疗。其中顺铂组采取紫杉醇+顺铂方案,洛铂组接受紫杉醇+洛铂方案。比较治疗前后2组患者临床疗效及KPS评分,并对Ig A、Ig G、Ig M、CD4+及CD8+指标水平进行分析。结果:洛铂组有效率(CR+PR)为87.2%(41/47),与顺铂组[80.8%(38/47)]差异无统计学意义(P>0.05)。洛铂组术后KPS评分及CD4+水平高于顺铂组(P<0.05),但CD8+水平低于顺铂组(P<0.05),差异有统计学意义;2组患者手术前后Ig A、Ig G及Ig M均无统计学意义(P>0.05)。洛铂组毒副反应发生率低于顺铂组(P<0.05)。结论:含洛铂术前辅助化疗方案有助于改善非小细胞肺癌患者的免疫功能,降低化疗的毒副反应。
Objective: To investigate the clinical efficacy of different chemotherapy regimens combined with surgical treatment of non-small cell lung cancer and its impact on immune function. Methods: Ninety-four patients with non-small cell lung cancer confirmed by pathology were divided into cisplatin group and lobaplatin group by random number table method, with 47 cases in each group. Patients in both groups underwent surgical treatment and received adjuvant chemotherapy before surgery. Among them, the cisplatin group received paclitaxel + cisplatin regimen, and the lobaplatin group received paclitaxel + lobaplatin regimen. The clinical efficacy and KPS scores were compared between the two groups before and after treatment, and the levels of Ig A, Ig G, Ig M, CD4 + and CD8 + were analyzed. Results: The effective rate (CR + PR) in lobaplatin group was 87.2% (41/47), which was not significantly different from that in cisplatin group [80.8% (38/47)] (P> 0.05). The KPS scores and CD4 + levels in the lobaplatin group were significantly higher than those in the cisplatin group (P <0.05), but the levels of CD8 + were lower than those in the cisplatin group (P <0.05) Ig M were not statistically significant (P> 0.05). The incidence of side effects of lobaplatin group was lower than that of cisplatin group (P <0.05). Conclusion: Preoperative adjuvant chemotherapy with lobaplatin may help to improve the immune function of patients with non-small cell lung cancer and reduce the side effects of chemotherapy.